• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在竞争风险环境下使用嵌套病例对照研究设计估计相对和绝对风险:来自 ProMort 研究的实例。

Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study.

机构信息

Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.

出版信息

Am J Epidemiol. 2019 Jun 1;188(6):1165-1173. doi: 10.1093/aje/kwz026.

DOI:10.1093/aje/kwz026
PMID:30976789
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8210820/
Abstract

In this paper, we describe the Prognostic Factors for Mortality in Prostate Cancer (ProMort) study and use it to demonstrate how the weighted likelihood method can be used in nested case-control studies to estimate both relative and absolute risks in the competing-risks setting. ProMort is a case-control study nested within the National Prostate Cancer Register (NPCR) of Sweden, comprising 1,710 men diagnosed with low- or intermediate-risk prostate cancer between 1998 and 2011 who died from prostate cancer (cases) and 1,710 matched controls. Cause-specific hazard ratios and cumulative incidence functions (CIFs) for prostate cancer death were estimated in ProMort using weighted flexible parametric models and compared with the corresponding estimates from the NPCR cohort. We further drew 1,500 random nested case-control subsamples of the NPCR cohort and quantified the bias in the hazard ratio and CIF estimates. Finally, we compared the ProMort estimates with those obtained by augmenting competing-risks cases and by augmenting both competing-risks cases and controls. The hazard ratios for prostate cancer death estimated in ProMort were comparable to those in the NPCR. The hazard ratios for dying from other causes were biased, which introduced bias in the CIFs estimated in the competing-risks setting. When augmenting both competing-risks cases and controls, the bias was reduced.

摘要

在本文中,我们描述了前列腺癌死亡率预后因素(ProMort)研究,并利用它展示如何在嵌套病例对照研究中使用加权似然法来估计竞争风险环境下的相对风险和绝对风险。ProMort 是一项嵌套在瑞典国家前列腺癌登记处(NPCR)中的病例对照研究,包含 1710 名 1998 年至 2011 年间被诊断为低危或中危前列腺癌且死于前列腺癌的男性(病例)和 1710 名匹配对照。使用加权灵活参数模型在 ProMort 中估计了前列腺癌死亡的特异性危险比和累积发病率函数(CIF),并与 NPCR 队列中的相应估计值进行了比较。我们进一步从 NPCR 队列中随机抽取了 1500 个嵌套病例对照子样本,并量化了危险比和 CIF 估计值的偏倚。最后,我们将 ProMort 的估计值与通过增加竞争风险病例和同时增加竞争风险病例和对照获得的估计值进行了比较。ProMort 估计的前列腺癌死亡率的危险比与 NPCR 中的相似。死于其他原因的危险比存在偏差,这导致竞争风险环境下估计的 CIF 存在偏差。当同时增加竞争风险病例和对照时,偏差会减少。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6510/8210820/a7025116b44c/kwz026f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6510/8210820/a7025116b44c/kwz026f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6510/8210820/a7025116b44c/kwz026f01.jpg

相似文献

1
Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study.在竞争风险环境下使用嵌套病例对照研究设计估计相对和绝对风险:来自 ProMort 研究的实例。
Am J Epidemiol. 2019 Jun 1;188(6):1165-1173. doi: 10.1093/aje/kwz026.
2
Absolute risk from double nested case-control designs: cause-specific proportional hazards models with and without augmented estimating equations.双重巢式病例对照设计的绝对风险:有和没有扩充估计方程的病因特异性比例风险模型。
Biometrics. 2024 Jul 1;80(3). doi: 10.1093/biomtc/ujae062.
3
Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.在瑞典,与斯堪的纳维亚前列腺癌研究组 4 期(SPCG-4)研究相比,在匹配的当代队列中接受根治性前列腺切除术的患者的死亡率。
BJU Int. 2019 Mar;123(3):421-428. doi: 10.1111/bju.14563. Epub 2018 Oct 25.
4
Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments.治疗加权竞争风险的逆概率分析:前列腺癌治疗后泌尿系统不良事件长期风险的应用
BMC Med Res Methodol. 2017 Jul 10;17(1):93. doi: 10.1186/s12874-017-0367-8.
5
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.基于组织的基因组学在中高危男性自然史队列中增强了前列腺切除术后风险分层。
Eur Urol. 2016 Jan;69(1):157-65. doi: 10.1016/j.eururo.2015.05.042. Epub 2015 Jun 6.
6
How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden.如何使癌症生存统计数据对患者和临床医生更有用:以瑞典局限性前列腺癌为例。
Cancer Causes Control. 2013 Mar;24(3):505-15. doi: 10.1007/s10552-012-0141-5. Epub 2013 Jan 8.
7
Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.非治愈性治疗局部晚期前列腺癌男性患者的死亡率:瑞典 PCBaSe 全国性研究。
Eur Urol. 2011 Sep;60(3):554-63. doi: 10.1016/j.eururo.2011.05.047. Epub 2011 Jun 1.
8
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.局部晚期前列腺癌男性患者的短期雄激素抑制和放疗与中期雄激素抑制和放疗,联合或不联合唑来膦酸治疗(TROG 03.04 RADAR):一项随机、3 期、析因试验的 10 年结果。
Lancet Oncol. 2019 Feb;20(2):267-281. doi: 10.1016/S1470-2045(18)30757-5. Epub 2018 Dec 19.
9
On the choice of timescale for other cause mortality in a competing risk setting using flexible parametric survival models.在竞争风险环境中使用灵活参数生存模型选择其他原因死亡率的时间尺度。
Biom J. 2022 Oct;64(7):1161-1177. doi: 10.1002/bimj.202100254. Epub 2022 Jun 16.
10
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.年龄、肿瘤风险和合并症对美国前列腺癌男性基于人群队列生存竞争风险的影响。
Ann Intern Med. 2013 May 21;158(10):709-17. doi: 10.7326/0003-4819-158-10-201305210-00005.

引用本文的文献

1
Absolute risk from double nested case-control designs: cause-specific proportional hazards models with and without augmented estimating equations.双重巢式病例对照设计的绝对风险:有和没有扩充估计方程的病因特异性比例风险模型。
Biometrics. 2024 Jul 1;80(3). doi: 10.1093/biomtc/ujae062.
2
Weighted metrics are required when evaluating the performance of prediction models in nested case-control studies.在嵌套病例对照研究中评估预测模型的性能时,需要使用加权指标。
BMC Med Res Methodol. 2024 May 17;24(1):115. doi: 10.1186/s12874-024-02213-6.
3
Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort.

本文引用的文献

1
Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies.从存档福尔马林固定石蜡包埋前列腺活检中提取的核酸的数量和质量。
BMC Med Res Methodol. 2018 Dec 5;18(1):161. doi: 10.1186/s12874-018-0628-1.
2
Analysis of Nested Case-Control Study Designs: Revisiting the Inverse Probability Weighting Method.巢式病例对照研究设计分析:重新审视逆概率加权法
Commun Stat Appl Methods. 2013 Nov;20(6):455-466. doi: 10.5351/CSAM.2013.20.6.455.
3
Comparisons of risk prediction methods using nested case-control data.
队列简介:都灵前列腺癌预后(TPCP)队列。
Front Oncol. 2023 Oct 6;13:1242639. doi: 10.3389/fonc.2023.1242639. eCollection 2023.
4
Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer.光学显微镜和虚拟显微镜在前列腺癌组织病理学评估中的可互换性。
Sci Rep. 2021 Feb 5;11(1):3257. doi: 10.1038/s41598-021-82911-z.
5
ERRATUM: "ESTIMATION OF RELATIVE AND ABSOLUTE RISKS IN A COMPETING-RISKS SETTING USING A NESTED CASE-CONTROL STUDY DESIGN: EXAMPLE FROM THE PROMORT STUDY".勘误:“使用巢式病例对照研究设计估计竞争风险环境中的相对风险和绝对风险:来自PROMORT研究的示例”。
Am J Epidemiol. 2020 Oct 1;189(10):1213. doi: 10.1093/aje/kwaa034.
使用巢式病例对照数据对风险预测方法进行比较。
Stat Med. 2017 Feb 10;36(3):455-465. doi: 10.1002/sim.7143. Epub 2016 Oct 13.
4
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.2014年国际泌尿病理学会(ISUP)前列腺癌Gleason分级共识会议:分级模式的定义及新分级系统的建议
Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530.
5
Nested case-control studies: should one break the matching?巢式病例对照研究:是否应该打破匹配?
Lifetime Data Anal. 2015 Oct;21(4):517-41. doi: 10.1007/s10985-015-9319-y. Epub 2015 Jan 23.
6
A new comparison of nested case-control and case-cohort designs and methods.嵌套病例对照研究与病例队列研究设计及方法的新比较。
Eur J Epidemiol. 2015 Mar;30(3):197-207. doi: 10.1007/s10654-014-9974-4. Epub 2014 Dec 2.
7
Capture rate and representativity of The National Prostate Cancer Register of Sweden.瑞典国家前列腺癌登记处的捕获率和代表性。
Acta Oncol. 2015 Feb;54(2):158-63. doi: 10.3109/0284186X.2014.939299. Epub 2014 Jul 18.
8
Analysis of secondary outcomes in nested case-control study designs.巢式病例对照研究设计中的次要结局分析。
Stat Med. 2014 Oct 30;33(24):4215-26. doi: 10.1002/sim.6231. Epub 2014 Jun 12.
9
Reuse of controls in nested case-control studies.巢式病例对照研究中对照的重复使用。
Epidemiology. 2014 Mar;25(2):315-7. doi: 10.1097/EDE.0000000000000057.
10
Prostate cancer: summary of updated NICE guidance.前列腺癌:英国国家卫生与临床优化研究所(NICE)最新指南摘要
BMJ. 2014 Jan 8;348:f7524. doi: 10.1136/bmj.f7524.